4D Path
Agent30Agent Readiness: 30/100. Below median. Measured by StartupHub.ai. Median 41.Trust88Data Trust: 88/100. Top 25%. Measured by StartupHub.ai. Median 61.Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.
About this profileCompany details: from public sourcesFunding: no announced round on fileOwnership: not yet claimed by the companyScores: measured by named tools; each links to its methodOur rules
About
4D Path has created the QPOR™ Platform, a groundbreaking solution designed to directly measure and quantify cell cycle deregulations and tumor microenvironment dynamics. This platform precisely predicts a patient's response to therapy, enabling researchers and clinicians to understand which treatment most effectively targets a patient's specific tumor. 4D Path partners with others to deliver customized treatment prediction signatures for therapies, aiming to provide a true treatment match for cancer patients.
Listed competitors
Genomics and AI-driven health intelligence company focused on extending healthy human life.
Global biopharmaceutical company focused on oncology and neuroscience treatments.
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Also in this space
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Drug Discovery
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, HealthTech
Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.
Shares Biotechnology, Artificial Intelligence
Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
Shares Biotechnology, Oncology
Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.
Shares Biotechnology, Drug Discovery
Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
Shares Biotechnology, Artificial Intelligence
Key facts
- Website
- 4dpath.com
- Headquarters
- Newton, Massachusetts, USA
- Founded
- 2016
- Employees
- 17
- Total funding
- $17M (Strategic financing)
- Business model
- B2B2C
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 5 May 2026 | Strategic financing | Undisclosed | |
| 3 May 2023 | Series A | $13M | |
| 10 Dec 2019 | Seed | $4M |
Tech stack
Detected on 4dpath.com, last scanned 22 Oct 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Auth
- Auth0
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
- Video / media
- YouTube
4D Path scores 17. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is 4D Path trustworthy and reputable?
StartupHub's Data Trust & Reputation score for 4D Path is 88 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has 4D Path raised?
4D Path has raised a total of $17M in funding. The most recent round on record is Strategic financing.
How many employees does 4D Path have?
4D Path has approximately 17 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for 4D Path
